# Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU

> **NCT00628862** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 613 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Formoterol Turbuhaler® 4.5mg
- **DRUG:** Formoterol Turbuhaler® 9 mg
- **DRUG:** Turbuhaler® placebo

## Key facts

- **NCT ID:** NCT00628862
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 613 (ACTUAL)
- **Last updated:** 2012-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628862, "Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00628862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*